On Thursday, April 10, 2025, the Forum for Collaborative Research convened its 12th TAVI Forum in Vienna, Austria
Materials
Presentations
Introductory Remarks 
Welcome and Introductions
Shilpa Mitra, Forum for Collaborative Research
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska University Hospital
Camille Kotton, Massachusetts General Hospital
Session I: Industry Roundtable
Pritelivir for the Treatment of Refractory HSV Infection in Immunocompromised Patients
Cynthia Wat, AiCuris
AIC468 for the Treatment of BKV Infection in Immunocompromised Patients
Peter Lischka, AiCurisPotravitug as Treatment of BKV Infection in Kidney Transplant Recipients
Juergen Beck, Memo Therapeutics
Brincidofovir (BCV) for post-HCT Adenovirus Infection
Nkechi Azie, Symbio Pharmaceuticals USA Inc
BCV efficacy against AdV: Update on molecular typing
Thomas Lion, Labdia LabordiagnostikPreventing Transplantation-Associated CMV Reactivation and Disease with Ex Vivo Perfusion
Ian McGowan, Synklino
Panel Discussion
All Meeting Participants
Session II: Measles in Immunocompromised Populations Persistent Threats, Prevention Gaps, and Therapeutic Uncertainty
Ricardo La Hoz*, UT Southwestern Medical Center
Discussion
All Meeting Participants
Session III: New Topics in Transplant & Immunocompromised Populations
H5N1 Update and Implications for the Immunocompromised Host
Michael Ison*, NIAID/NIH
Discussion
All Meeting ParticipantsCombination Therapy for Treatment of CMV
Camille Kotton, Massachusetts General Hospital
Discussion
All Meeting ParticipantsHepatitis B Surface Antigen Positive Donors in Organ Transplantation
Camille Kotton, Massachusetts General Hospital
Discussion
All Meeting Participants
Concluding Remarks
Next Steps
Veronica Miller, Forum for Collaborative Research
Per Ljungman, Karolinska University Hospital
Camille Kotton, Massachusetts General Hospital
*Remote participation